Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

Petrolatum 2Fluorouracil 2trametinib 1talimogene laherparepvec 1sargramostim 1reolysin 1pimonidazole 1pembrolizumab 1fluoromisonidazole 1dabrafenib 1Trimethoprim, Sulfamethoxazole Drug Combination 1Surgical Procedures, Operative 1Sugars 1Radiotherapy 1Radiation 1Povidone-Iodine 1Melphalan 1Granulocyte-Macrophage Colony-Stimulating Factor 1Erlotinib Hydrochloride 1Clindamycin 1Clarithromycin 1Cephalexin 1Azithromycin 1Anti-Bacterial Agents 1Amoxicillin 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Skin Neoplasms × fluoromisonidazole × Clear all
NCT02061007 2016-05-09

Biomarker Correlates of Hypoxia in Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Withdrawn
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡